301103 何氏眼科
已收盘 08-28 15:00:00
资讯
新帖
简况
何氏眼科（301103）2026年中报简析：增收不增利，公司应收账款体量较大
证券之星 · 08-29 06:50
何氏眼科（301103）2026年中报简析：增收不增利，公司应收账款体量较大
何氏眼科(301103)6月30日股东户数0.97万户，较上期减少0.52%
证券之星 · 08-27
何氏眼科(301103)6月30日股东户数0.97万户，较上期减少0.52%
何氏眼科2026年半年报：屈光业务放量，表观净利承压
蓝鲸财经 · 08-27
何氏眼科2026年半年报：屈光业务放量，表观净利承压
何氏眼科(301103.SZ)发布上半年业绩，归母净利润4153.33万元，同比下降6.30%
智通财经 · 08-27
何氏眼科(301103.SZ)发布上半年业绩，归母净利润4153.33万元，同比下降6.30%
何氏眼科（301103）披露董事会换届选举结果，8月6日股价下跌0.12%
证券之星 · 08-06
何氏眼科（301103）披露董事会换届选举结果，8月6日股价下跌0.12%
何氏眼科：选举李丽娟为职工代表董事
财中社 · 08-06
何氏眼科：选举李丽娟为职工代表董事
何氏眼科（301103）披露董事会换届选举议案，7月21日股价下跌3.13%
证券之星 · 07-21
何氏眼科（301103）披露董事会换届选举议案，7月21日股价下跌3.13%
何氏眼科：参股产业基金聚焦眼科产业链上下游核心领域
证券之星 · 07-02
何氏眼科：参股产业基金聚焦眼科产业链上下游核心领域
何氏眼科跌3.1% 2022年上市募13亿元中原证券保荐
中金财经 · 06-30
何氏眼科跌3.1% 2022年上市募13亿元中原证券保荐
何氏眼科：目前未涉及开展眼科手术机器人自研工作
证券之星 · 06-17
何氏眼科：目前未涉及开展眼科手术机器人自研工作
何氏眼科：公司管理层努力做好经营和管理
证券之星 · 06-15
何氏眼科：公司管理层努力做好经营和管理
何氏眼科：持续夯实眼科主业
证券之星 · 06-05
何氏眼科：持续夯实眼科主业
何氏眼科：自研智能视网膜健康评估系统已在院内医院辅助应用
证券之星 · 05-27
何氏眼科：自研智能视网膜健康评估系统已在院内医院辅助应用
股市必读：何氏眼科（301103）5月25日披露最新机构调研信息
证券之星 · 05-26
股市必读：何氏眼科（301103）5月25日披露最新机构调研信息
何氏眼科：5月25日接受机构调研，招商医药、圆信永丰基金等多家机构参与
证券之星 · 05-25
何氏眼科：5月25日接受机构调研，招商医药、圆信永丰基金等多家机构参与
【机构调研记录】申万菱信基金调研何氏眼科、华源控股
证券之星 · 05-18
【机构调研记录】申万菱信基金调研何氏眼科、华源控股
股市必读：何氏眼科（301103）5月15日披露最新机构调研信息
证券之星 · 05-18
股市必读：何氏眼科（301103）5月15日披露最新机构调研信息
何氏眼科：关于募集资金使用
证券之星 · 05-15
何氏眼科：关于募集资金使用
何氏眼科（301103）披露持股5%以上股东减持计划实施完成公告，5月8日股价上涨0.91%
证券之星 · 05-08
何氏眼科（301103）披露持股5%以上股东减持计划实施完成公告，5月8日股价上涨0.91%
5月7日何氏眼科发布公告，股东减持73.33万股
证券之星 · 05-07
5月7日何氏眼科发布公告，股东减持73.33万股
加载更多
公司概况
公司名称：
辽宁何氏眼科医院集团股份有限公司
所属行业：
卫生
上市日期：
2022-03-22
主营业务：
辽宁何氏眼科医院集团股份有限公司的主营业务是向眼病患者提供眼科专科诊疗服务和视光服务。公司的主要产品是白内障诊疗服务、屈光不正手术矫正服务、玻璃体视网膜诊疗服务、其他手术诊疗服务项目。
发行价格：
42.50
{"stockData":{"symbol":"301103","market":"SZ","secType":"STK","nameCN":"何氏眼科","latestPrice":16.5,"timestamp":1787900589000,"preClose":16.66,"halted":0,"volume":2059043,"delay":0,"changeRate":-0.0096,"floatShares":122000000,"shares":158000000,"eps":0.1554,"marketStatus":"已收盘","change":-0.16,"latestTime":"08-28 15:00:00","open":16.65,"high":16.7,"low":16.37,"amount":33984900,"amplitude":0.0198,"askPrice":16.51,"askSize":50,"bidPrice":16.5,"bidSize":59,"shortable":0,"etf":0,"ttmEps":0.1554,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":5,"adr":0,"adjPreClose":16.66,"symbolType":"stock","openAndCloseTimeList":[[1787880600000,1787887800000],[1787893200000,1787900400000]],"highLimit":18.33,"lowLimit":14.99,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":158026471,"isCdr":false,"pbRate":1.37,"roa":"--","peRate":106.177606,"roe":"2.18%","epsLYR":0.173,"committee":0.659574,"marketValue":2607000000,"turnoverRate":0.0169,"status":1,"floatMarketCap":2007000000},"requestUrl":"/m/hq/s/301103/","defaultTab":"news","newsList":[{"id":"2663016266","title":"何氏眼科（301103）2026年中报简析：增收不增利，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2663016266","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663016266?lang=zh_cn&edition=full","pubTime":"2026-08-29 06:50","pubTimestamp":1787957430,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期何氏眼科发布2026年中报。截至本报告期末，公司营业总收入5.85亿元，同比上升4.46%，归母净利润4153.33万元，同比下降6.3%。本报告期何氏眼科公司应收账款体量较大，当期应收账款占最新年报归母净利润比达113.48%。本次财报公布的各项数据指标表现一般。财报体检工具显示：建议关注公司应收账款状况本文数据来源于何氏眼科2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900013137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662070305","title":"何氏眼科(301103)6月30日股东户数0.97万户，较上期减少0.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662070305","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662070305?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:18","pubTimestamp":1787825888,"startTime":"0","endTime":"0","summary":"证券之星消息，近日何氏眼科披露，截至2026年6月30日公司股东户数为9715.0户，较3月31日减少51.0户，减幅为0.52%。在医疗服务行业个股中，何氏眼科股东户数低于行业平均水平，截至6月30日，医疗服务行业平均股东户数为4.75万户。从股价来看，2026年3月31日至2026年6月30日，何氏眼科区间跌幅为23.09%，在此期间股东户数减少51.0户，减幅为0.52%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700043911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662703852","title":"何氏眼科2026年半年报：屈光业务放量，表观净利承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2662703852","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662703852?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:06","pubTimestamp":1787825170,"startTime":"0","endTime":"0","summary":"报告期内，屈光业务表现亮眼，实现收入1.58亿元，同比增长16.66%，毛利率提升1.39个百分点至54.94%，主要得益于全飞秒、ICL等高端术式推广及手术量同比增长9%。相比之下，受医保控费及耗材集采常态化影响，白内障诊疗收入同比下降7.16%，毛利率下降5.32个百分点至35.04%。后续需重点关注屈光手术量的持续性及加盟店转化效率，以及医保政策变化对白内障等基础业务毛利率的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787818380445418719","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["301103","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662777929","title":"何氏眼科(301103.SZ)发布上半年业绩，归母净利润4153.33万元，同比下降6.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662777929","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662777929?lang=zh_cn&edition=full","pubTime":"2026-08-27 17:23","pubTimestamp":1787822597,"startTime":"0","endTime":"0","summary":"智通财经APP讯，何氏眼科(301103.SZ)发布2026年半年度报告，报告期内，公司实现营业收入5.85亿元，同比增长4.46%。实现归属于上市公司股东的净利润4153.33万元，同比下降6.30%。实现归属于上市公司股东的扣除非经常性损益的净利润3475.93万元，同比下降6.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301103"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657658642","title":"何氏眼科（301103）披露董事会换届选举结果，8月6日股价下跌0.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657658642","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657658642?lang=zh_cn&edition=full","pubTime":"2026-08-06 22:45","pubTimestamp":1786027518,"startTime":"0","endTime":"0","summary":"截至2026年8月6日收盘，何氏眼科报收于16.09元，较前一交易日下跌0.12%，最新总市值为25.43亿元。该股当日开盘16.05元，最高16.19元，最低15.87元，成交额达2705.07万元，换手率为1.39%。公司于近日披露《2026年第三次临时股东会决议公告》，显示辽宁何氏眼科医院集团股份有限公司于2026年8月6日召开2026年第三次临时股东会，会议采用现场与网络投票相结合方式，审议通过董事会换届选举议案。出席会议股东共32人，代表有表决权股份总数的54.5608%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600040203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636512","title":"何氏眼科：选举李丽娟为职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636512","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657636512?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:29","pubTimestamp":1786015740,"startTime":"0","endTime":"0","summary":"8月6日，何氏眼科（301103）发布公告，公司召开职工代表大会，选举李丽娟为第四届董事会职工代表董事。2026年一季度，何氏眼科实现收入3.05亿元，归母净利润3269万元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-06/doc-inimksmf3808276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301103","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653248205","title":"何氏眼科（301103）披露董事会换届选举议案，7月21日股价下跌3.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653248205","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653248205?lang=zh_cn&edition=full","pubTime":"2026-07-21 22:32","pubTimestamp":1784644363,"startTime":"0","endTime":"0","summary":"截至2026年7月21日收盘，何氏眼科报收于15.18元，较前一交易日下跌3.13%，最新总市值为23.99亿元。该股当日开盘15.63元，最高15.66元，最低14.8元，成交额达5054.68万元，换手率为2.75%。近日，辽宁何氏眼科医院集团股份有限公司披露《关于召开2026年第三次临时股东会的通知》。股权登记日为2026年8月3日，登记时间截至2026年8月4日。中小投资者投票结果将单独统计披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100045051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648500959","title":"何氏眼科：参股产业基金聚焦眼科产业链上下游核心领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2648500959","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648500959?lang=zh_cn&edition=full","pubTime":"2026-07-02 20:48","pubTimestamp":1782996487,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科07月01日在投资者关系平台上答复投资者关心的问题。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200039466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647053994","title":"何氏眼科跌3.1% 2022年上市募13亿元中原证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2647053994","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647053994?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:03","pubTimestamp":1782810195,"startTime":"0","endTime":"0","summary":"中国经济网北京6月30日讯 何氏眼科 今日收报14.98元，跌幅3.10%。 何氏眼科首次公开发行股票的发行费用总额为13,193.87万元，其中，保荐承销费用9,990.49万元。 何氏眼科披露的2021年度分红派息、转增股本实施公告显示，公司于2022年5月19日召开的2021年年度股东大会审议通过了《关于2021年度利润分配及资本公积金转增股本预案的议案》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260630/32294805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","BK0201","301103","601375","BK0236","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644746036","title":"何氏眼科：目前未涉及开展眼科手术机器人自研工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2644746036","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644746036?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:52","pubTimestamp":1781700722,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科(301103)06月16日在投资者关系平台上答复投资者关心的问题。投资者提问：何总：公司的眼科机器人什么情况？何氏眼科回复：尊敬的投资者您好，公司高度重视智慧医疗与数字化建设，目前未涉及开展眼科手术机器人自研工作。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700039433.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643899275","title":"何氏眼科：公司管理层努力做好经营和管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2643899275","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643899275?lang=zh_cn&edition=full","pubTime":"2026-06-15 15:45","pubTimestamp":1781509522,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科(301103)06月15日在投资者关系平台上答复投资者关心的问题。投资者提问：何总:公司股价已逼近净资产价格了？有考虑采取措施维护二级市场稳定吗？何氏眼科回复：尊敬的投资者您好！公司股价的波动受市场整体情绪、行业板块轮动、资金偏好等多重因素综合影响。短期市场表现不一定完全匹配公司内在价值。公司管理层努力做好经营和管理，依法合规并积极探索行之有效的市值管理方式和路径，持续提升公司内在价值，为股东及利益相关方谋求长期稳定的投资回报。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500014679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641148409","title":"何氏眼科：持续夯实眼科主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2641148409","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641148409?lang=zh_cn&edition=full","pubTime":"2026-06-05 20:48","pubTimestamp":1780663689,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科06月04日在投资者关系平台上答复投资者关心的问题。公司坚信，扎实经营、兑现股权激励业绩考核目标，是从基本面支撑长期价值、保障股权激励实效、稳固员工信心的根本路径。如后续出台相关计划，将严格按照法律法规及交易所规则，履行决策程序并及时披露相关信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500038638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638735625","title":"何氏眼科：自研智能视网膜健康评估系统已在院内医院辅助应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2638735625","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638735625?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:36","pubTimestamp":1779853014,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科(301103)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司领导：公司是否有，利用AI视网膜大数据诊断的项目？如果有，现在是什么情况？谢谢回复！何氏眼科回复：尊敬的投资者您好，公司全资子公司辽宁蜻蜓健康科技有限公司自研智能视网膜健康评估系统、视网膜血管智能量化分析等算法，已在公司院内医院辅助应用，筛查体系于门店、校园及社区落地。相关眼病筛查及视网膜定量分析算法数据资产已在北京国际大数据交易所登记存证。上述项目对公司当前主营业务开展或业绩未造成重大影响，敬请谨慎决策、注意投资风险。谢谢！以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019966.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638554046","title":"股市必读：何氏眼科（301103）5月25日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2638554046","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638554046?lang=zh_cn&edition=full","pubTime":"2026-05-26 02:40","pubTimestamp":1779734422,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘，何氏眼科报收于18.18元，下跌0.66%，换手率1.43%，成交量1.74万手，成交额3185.36万元。来自机构调研要点：屈光业务在2025年实现营收与毛利率双增长，2026年一季度延续“量价齐升”趋势。答：公司整体毛利率稳中有升，2025年医疗行业毛利率40.50%，其中屈光、视光为高毛利核心，白内障通过结构升级企稳。股权激励层面，公司已落地2025年限制性股票激励计划，绑定核心团队与公司发展利益，助力长期发展，充分调动经营积极性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600001817.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638353785","title":"何氏眼科：5月25日接受机构调研，招商医药、圆信永丰基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2638353785","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638353785?lang=zh_cn&edition=full","pubTime":"2026-05-25 19:01","pubTimestamp":1779706911,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年5月25日何氏眼科发布公告称公司于2026年5月25日接受机构调研，招商医药、圆信永丰基金、拾贝投资参与。何氏眼科2026年一季报显示，一季度公司主营收入3.05亿元，同比上升4.7%；归母净利润3268.88万元，同比上升0.48%；扣非净利润3081.18万元，同比下降1.21%；负债率13.94%，投资收益153.46万元，财务费用159.7万元，毛利率44.24%。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500026937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","09939","159938","301103","BK1574","BK0236","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636012657","title":"【机构调研记录】申万菱信基金调研何氏眼科、华源控股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636012657","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636012657?lang=zh_cn&edition=full","pubTime":"2026-05-18 08:02","pubTimestamp":1779062553,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月15日披露的机构调研信息，申万菱信基金近期对2家上市公司进行了调研，相关名单如下：1）何氏眼科 调研纪要：2025年度，公司视光业务实现收入3.48亿元，占营业收入比重为31.84%，毛利率为42.10%；屈光业务实现收入2.34亿元，占营业收入比重为21.43%，毛利率为50.27%；白内障业务实现收入1.45亿元，占营业收入比重为13.27%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800002722.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0132","BK0236","BK0256","002787"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636701669","title":"股市必读：何氏眼科（301103）5月15日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2636701669","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636701669?lang=zh_cn&edition=full","pubTime":"2026-05-18 03:54","pubTimestamp":1779047652,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，何氏眼科报收于18.72元，下跌1.58%，换手率1.82%，成交量2.22万手，成交额4183.85万元。来自机构调研要点：视光业务2025年收入占比31.84%，毛利率为42.10%，为公司核心业务之一。2026年第一季度，公司屈光业务延续增长态势，实现量价齐升。1至2月受益于寒假及春节旺季，业务量与收入双位数同比增长；3月环比回落，但同比增速加快。2025年白内障业务营收1.45亿元，同比下降7.43%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800001609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635082736","title":"何氏眼科：关于募集资金使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2635082736","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635082736?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:51","pubTimestamp":1778849494,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科05月14日在投资者关系平台上答复投资者关心的问题。关于募集资金使用：公司严格按照《募集资金管理办法》及相关监管要求使用募集资金。公司将持续优化募集资金使用效率，加快主业项目落地，提升经营业绩；同时完善股东回报机制，综合运用现金分红、合理资金配置等方式回馈投资者，切实维护全体股东及利益相关方的长远利益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500041094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633553432","title":"何氏眼科（301103）披露持股5%以上股东减持计划实施完成公告，5月8日股价上涨0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633553432","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633553432?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:13","pubTimestamp":1778235229,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，何氏眼科报收于19.95元，较前一交易日上涨0.91%，最新总市值为31.53亿元。本次减持计划实施期间为2026年2月7日至2026年5月6日，减持价格为20.03元/股。减持后，该股东持股比例由6.54%降至6.07%。公告显示，本次减持未违反相关法规，不影响公司控制权，减持计划已实施完成，且与此前披露计划一致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800033864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145465","title":"5月7日何氏眼科发布公告，股东减持73.33万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145465","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633145465?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:01","pubTimestamp":1778151696,"startTime":"0","endTime":"0","summary":"证券之星消息，5月7日何氏眼科发布公告《何氏眼科:关于持股5%以上股东减持计划实施完成的公告》，其股东先进制造产业投资基金(有限合伙)于2026年4月27日至2026年5月6日间合计减持73.33万股，占公司目前总股本的0.464%，变动期间该股股价上涨0.05%，截止5月6日收盘报19.75元。股东增减持详情见下表：根据何氏眼科2026年一季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700034290.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788120301602,"stockEarnings":[{"period":"1week","weight":-0.0143},{"period":"1month","weight":0.0707},{"period":"3month","weight":-0.0294},{"period":"6month","weight":-0.2373},{"period":"1year","weight":-0.2534},{"period":"ytd","weight":-0.1518}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.0323},{"period":"3month","weight":-0.0286},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0283},{"period":"ytd","weight":-0.0042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"辽宁何氏眼科医院集团股份有限公司","boardCode":"AI0083","boardName":"卫生","stockholders":"9715人(较上一季度减少0.52%)","perCapita":"12520股","listingDate":"2022-03-22","address":"辽宁省沈阳市浑南区天赐街5-1号(607)","registeredCapital":"15802万元","survey":" 辽宁何氏眼科医院集团股份有限公司的主营业务是向眼病患者提供眼科专科诊疗服务和视光服务。公司的主要产品是白内障诊疗服务、屈光不正手术矫正服务、玻璃体视网膜诊疗服务、其他手术诊疗服务项目。","listedPrice":42.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"何氏眼科(301103)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供何氏眼科(301103)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"何氏眼科,301103,何氏眼科股票,何氏眼科股票老虎,何氏眼科股票老虎国际,何氏眼科行情,何氏眼科股票行情,何氏眼科股价,何氏眼科股市,何氏眼科股票价格,何氏眼科股票交易,何氏眼科股票购买,何氏眼科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"何氏眼科(301103)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供何氏眼科(301103)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}